PURIFIED CORTROPHIN GEL (repository corticotropin) by ANI Pharmaceuticals is unknown. Approved for exacerbations of multiple sclerosis in adults, acute exacerbations of multiple sclerosis in adults, multiple sclerosis and 3 more indications. First approved in 1954.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
Purified Cortrophin Gel is a repository corticotropin (ACTH) injection that stimulates the adrenal cortex to produce cortisol and other steroid hormones. It is indicated for acute exacerbations of multiple sclerosis and rheumatoid arthritis. The mechanism of action involves binding to melanocortin receptors and stimulating adrenal hormone release via cyclic AMP pathways, though the precise mechanism remains incompletely understood.
The product is in peak commercial stage with patent protection through 2043, suggesting a stable mid-sized franchise with sustained team investment.
unknown. Acthar Gel and endogenous ACTH stimulate the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances. Prolonged administration of large doses of Acthar Gel induces hyperplasia and hypertrophy of the adrenal cortex and continuous high…
Adrenocorticotropic Hormone
Worked on PURIFIED CORTROPHIN GEL at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Cortrophin offers mid-career stability in a niche immunology franchise with solid patent protection through 2043 and minimal generic erosion risk in the near term. Opportunities lean toward commercial execution (market development, patient access) rather than clinical innovation, making this an ideal fit for professionals focused on maximizing mature product value.